NCT03696277View on ClinicalTrials.gov

SAbR For Oligo-Progressive Renal Cell Cancer.

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

January 23, 2024

Study Completion Date

January 23, 2024

Conditions
Oligoprogressive Renal Cell Carcinoma
Interventions
RADIATION

Stereotactic ablative body radiation (SABR)

SAbR treatment regimens including ≥25Gy x1 fraction, ≥12Gy x 3 fractions, or ≥8Gy x 5 fractions.

Trial Locations (1)

75390

University of Texas Southwestern Medical Center, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER

NCT03696277 - SAbR For Oligo-Progressive Renal Cell Cancer. | Biotech Hunter | Biotech Hunter